Corsair Pharma, Inc. is a private biopharmaceutical company. The company has just announced the successful completion of a preclinical program for Its treprostinil Prodrug Transdermal System and its plans to start a Phase 1 trial in Q2 of 2025.
The Corsair transdermal patch is intended to provide steady and continuous blood levels of the prostacyclin drug treprostinil. The patch, applied once daily, would delivers an inactive prodrug (TRX-248), which crosses the skin, enters the blood and converts rapidly to treprostinil in the liver.
The patch intends to offer the benefits of infusion formulations by providing a steady supply of medication, while avoiding the disadvantages of the more invasive approaches, and with fewer expected side effects.
Read more at this link on Pulmonary Hypertension News and check out the company announcement here
See also our previous 2024 article on this topic at this link (the phase 1 trial has been delayed somewhat but we are delighted to hear this is now happening!
